Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This drug is a combination of two forms of the corticosteroid betamethasone—betamethasone dipropionate and betamethasone disodium phosphate—with the local anesthetic lidocaine. Betamethasone is a potent synthetic glucocorticoid with anti-inflammatory and immunosuppressive properties, acting primarily by inhibiting multiple inflammatory cytokines and suppressing leukocyte migration. The dipropionate form is typically used for topical or intralesional administration due to its prolonged action, while the disodium phosphate form is water-soluble and suitable for rapid onset via injection. Lidocaine acts as a local anesthetic by blocking voltage-gated sodium channels in neuronal cell membranes, thereby preventing pain signal transmission. This combination may be used in clinical settings where both rapid and sustained anti-inflammatory effects are desired along with immediate pain relief, such as in musculoskeletal injections or certain dermatological procedures[1][2][8].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on betamethasone dipropionate + betamethasone disodium phosphate + lidocaine.